keyword
https://read.qxmd.com/read/32518380/expression-and-prognostic-value-of-the-transcription-factors-egr1-and-egr3-in-gliomas
#21
JOURNAL ARTICLE
Arnon Møldrup Knudsen, Ida Eilertsen, Susanne Kielland, Mikkel Warming Pedersen, Mia Dahl Sørensen, Rikke Hedegaard Dahlrot, Henning Bünsow Boldt, Sune Munthe, Frantz Rom Poulsen, Bjarne Winther Kristensen
Most glioblastoma patients have a dismal prognosis, although some survive several years. However, only few biomarkers are available to predict the disease course. EGR1 and EGR3 have been linked to glioblastoma stemness and tumour progression, and this study aimed to investigate their spatial expression and prognostic value in gliomas. Overall 207 gliomas including 190 glioblastomas were EGR1/EGR3 immunostained and quantified. A cohort of 21 glioblastomas with high P53 expression and available tissue from core and periphery was stained with double-immunofluorescence (P53-EGR1 and P53-EGR3) and quantified...
June 9, 2020: Scientific Reports
https://read.qxmd.com/read/31058280/posttreatment-effect-of-mgmt-methylation-level-on-glioblastoma-survival
#22
JOURNAL ARTICLE
Rikke H Dahlrot, Pia Larsen, Henning B Boldt, Melissa S Kreutzfeldt, Steinbjørn Hansen, Jacob B Hjelmborg, Bjarne Winther Kristensen
The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) removes temozolomide-induced alkylation, thereby preventing DNA damage and cytotoxicity. We investigated the prognostic effect of different MGMT methylation levels on overall and progression-free survival in 327 patients with primary glioblastoma undergoing standard treatment. We obtained MGMT methylation level in 4 CpG sites using pyrosequencing. The association between MGMT methylation level and survival was investigated using Cox proportional hazards model and an extension to detect time-varying effects...
July 1, 2019: Journal of Neuropathology and Experimental Neurology
https://read.qxmd.com/read/30297697/aberrant-neuronal-differentiation-is-common-in-glioma-but-is-associated-neither-with-epileptic-seizures-nor-with-better-survival
#23
JOURNAL ARTICLE
Christoph Patrick Beier, Tine Rasmussen, Rikke Hedegaard Dahlrot, Helene Broch Tenstad, Julie Slinning Aarø, Mai Froberg Sørensen, Sólborg Berglind Heimisdóttir, Mia Dahl Sørensen, Per Svenningsen, Markus J Riemenschneider, Dagmar Beier, Bjarne Winther Kristensen
The mechanisms of glioma-associated seizures (GAS) have yet to be fully elucidated. Proneural subtype, isocitrate dehydrogenase 1 (IDH1) mutations, and epileptic seizures are closely associated suggesting that aberrant neuronal differentiation contributes to glioma-associated seizures. In a population-based cohort (n = 236), lack of stem cell marker expression (nestin, musashi) was significantly associated with IDH1 mutations and GAS at diagnosis. In vitro data suggested an association of IDH1 mutations and a more differentiated phenotype...
October 8, 2018: Scientific Reports
https://read.qxmd.com/read/29885671/evaluation-of-the-proliferation-marker-ki-67-in-gliomas-interobserver-variability-and-digital-quantification
#24
JOURNAL ARTICLE
Ljudmilla A G Nielsen, Julie A Bangsø, Kim H Lindahl, Rikke H Dahlrot, Jacob V B Hjelmborg, Steinbjørn Hansen, Bjarne W Kristensen
BACKGROUND: The Ki-67 Labelling Index (LI) is used as an ancillary tool in glioma diagnostics. Interobserver variability has been reported and no precise guidelines are available. Nor is it known whether novel digital approaches would be an advantage. Our aim was to evaluate the inter- and intraobserver variability of the Ki-67 LI between two pathologists and between pathologists and digital quantification both in whole tumour slides and in hot spots using narrow but diagnostically relevant intervals...
June 9, 2018: Diagnostic Pathology
https://read.qxmd.com/read/28837569/transferrin-receptor-1-and-ferritin-heavy-and-light-chains-in-astrocytic-brain-tumors-expression-and-prognostic-value
#25
JOURNAL ARTICLE
Ann Mari Rosager, Mia D Sørensen, Rikke H Dahlrot, Steinbjørn Hansen, David L Schonberg, Jeremy N Rich, Justin D Lathia, Bjarne W Kristensen
Astrocytic brain tumors are the most frequent primary brain tumors. Treatment with radio- and chemotherapy has increased survival making prognostic biomarkers increasingly important. The aim of the present study was to investigate the expression and prognostic value of transferrin receptor-1 (TfR1) as well as ferritin heavy (FTH) and light (FTL) chain in astrocytic brain tumors. A cohort of 111 astrocytic brain tumors (grade II-IV) was stained immunohistochemically with antibodies against TfR1, FTH, and FTL and scored semi-quantitatively...
2017: PloS One
https://read.qxmd.com/read/28767130/tumour-associated-microglia-macrophages-predict-poor-prognosis-in-high-grade-gliomas-and-correlate-with-an-aggressive-tumour-subtype
#26
JOURNAL ARTICLE
M D Sørensen, R H Dahlrot, H B Boldt, S Hansen, B W Kristensen
AIMS: Glioblastomas are highly aggressive and treatment resistant. Increasing evidence suggests that tumour-associated macrophages/microglia (TAMs) facilitate tumour progression by acquiring a M2-like phenotype. Our objective was to investigate the prognostic value of TAMs in gliomas using automated quantitative double immunofluorescence. METHODS: Samples from 240 patients with primary glioma were stained with antibodies against ionized calcium-binding adaptor molecule-1 (IBA-1) and cluster of differentiation 204 (CD204) to detect TAMs and M2-like TAMs...
February 2018: Neuropathology and Applied Neurobiology
https://read.qxmd.com/read/28677106/expression-and-prognostic-value-of-jam-a-in-gliomas
#27
JOURNAL ARTICLE
Ann Mari Rosager, Mia D Sørensen, Rikke H Dahlrot, Henning B Boldt, Steinbjørn Hansen, Justin D Lathia, Bjarne W Kristensen
Gliomas are among the most lethal cancers, being highly resistant to both chemo- and radiotherapy. The expression of junctional adhesion molecule-A (JAM-A) was recently identified on the surface of stem cell-like brain tumor-initiating cells and suggested to function as a unique glioblastoma niche adhesion factor influencing the tumorigenic potential of brain tumor-initiating cells. We have recently identified high JAM-A expression to be associated with poor outcome in glioblastomas, and our aim was to further investigate the expression of JAM-A in gliomas focusing especially on the prognostic value in WHO grade II and III gliomas...
October 2017: Journal of Neuro-oncology
https://read.qxmd.com/read/28662073/apng-as-a-prognostic-marker-in-patients-with-glioblastoma
#28
JOURNAL ARTICLE
Sigurd Fosmark, Sofie Hellwege, Rikke H Dahlrot, Kristian L Jensen, Helene Derand, Jesper Lohse, Mia D Sørensen, Steinbjørn Hansen, Bjarne W Kristensen
AIM: Expression of the base excision repair enzyme alkylpurine-DNA-N-glycosylase (APNG) has been correlated to temozolomide resistance. Our aim was to evaluate the prognostic value of APNG in a population-based cohort with 242 gliomas including 185 glioblastomas (GBMs). Cellular heterogeneity of GBMs was taken into account by excluding APNG expression in non-tumor cells from the analysis. METHODS: APNG expression was evaluated using automated image analysis and a novel quantitative immunohistochemical (IHC) assay (qIHC), where APNG protein expression was evaluated through countable dots...
2017: PloS One
https://read.qxmd.com/read/28574607/prognostic-value-of-o-6-methylguanine-dna-methyltransferase-mgmt-protein-expression-in-glioblastoma-excluding-nontumour-cells-from-the-analysis
#29
JOURNAL ARTICLE
R H Dahlrot, J Dowsett, S Fosmark, A Malmström, R Henriksson, H Boldt, K de Stricker, M D Sørensen, H S Poulsen, M Lysiak, P Söderkvist, J Rosell, S Hansen, B W Kristensen
AIMS: It is important to predict response to treatment with temozolomide (TMZ) in glioblastoma (GBM) patients. Both MGMT protein expression and MGMT promoter methylation status have been reported to predict the response to TMZ. We investigated the prognostic value of quantified MGMT protein levels in tumour cells and the prognostic importance of combining information of MGMT protein level and MGMT promoter methylation status. METHODS: MGMT protein expression was quantified in tumour cells in 171 GBMs from the population-based Region of Southern Denmark (RSD)-cohort using a double immunofluorescence approach...
February 2018: Neuropathology and Applied Neurobiology
https://read.qxmd.com/read/27171431/glioma-cells-in-the-tumor-periphery-have-a-stem-cell-phenotype
#30
JOURNAL ARTICLE
Sune Munthe, Stine Asferg Petterson, Rikke Hedegaard Dahlrot, Frantz Rom Poulsen, Steinbjørn Hansen, Bjarne Winther Kristensen
Gliomas are highly infiltrative tumors incurable with surgery. Although surgery removes the bulk tumor, tumor cells in the periphery are left behind resulting in tumor relapses. The aim of the present study was to characterize the phenotype of tumor cells in the periphery focusing on tumor stemness, proliferation and chemo-resistance. This was investigated in situ in patient glioma tissue as well as in orthotopic glioblastoma xenografts. We identified 26 gliomas having the R132 mutation in Isocitrate DeHydrogenase 1 (mIDH1)...
2016: PloS One
https://read.qxmd.com/read/26828563/development-and-validation-of-a-prognostic-model-for-recurrent-glioblastoma-patients-treated-with-bevacizumab-and-irinotecan
#31
JOURNAL ARTICLE
Thomas Urup, Rikke Hedegaard Dahlrot, Kirsten Grunnet, Ib Jarle Christensen, Signe Regner Michaelsen, Anders Toft, Vibeke Andrée Larsen, Helle Broholm, Michael Kosteljanetz, Steinbjørn Hansen, Hans Skovgaard Poulsen, Ulrik Lassen
BACKGROUND: Predictive markers and prognostic models are required in order to individualize treatment of recurrent glioblastoma (GBM) patients. Here, we sought to identify clinical factors able to predict response and survival in recurrent GBM patients treated with bevacizumab (BEV) and irinotecan. MATERIAL AND METHODS: A total of 219 recurrent GBM patients treated with BEV plus irinotecan according to a previously published treatment protocol were included in the initial population...
2016: Acta Oncologica
https://read.qxmd.com/read/26781160/trends-in-tumors-in-the-central-nervous-system-in-elderly-in-denmark-2008-2012
#32
JOURNAL ARTICLE
Rikke H Dahlrot, Frantz R Poulsen, Nina N T T Nguyen, Bjarne W Kristensen, Steinbjørn Hansen, Niels V Holm
BACKGROUND: Tumors in the central nervous system (CNS) comprise a heterogeneous group of tumors with different treatment strategies and prognoses. Current treatment regimens are based on studies on patients mainly younger than 70 years. The aim of the present study was to analyze and describe trends in incidence, mortality, prevalence, and relative survival in Denmark from 1980 to 2012 focusing on patients older than 70 years. MATERIAL AND METHODS: Tumors in the CNS were defined as ICD-10 codes C70-72, D32-33 and D42-43...
2016: Acta Oncologica
https://read.qxmd.com/read/25800004/high-levels-of-c-met-is-associated-with-poor-prognosis-in-glioblastoma
#33
JOURNAL ARTICLE
Stine Asferg Petterson, Rikke Hedegaard Dahlrot, Simon Kjær Hermansen, Sune K A Munthe, Michael Tveden Gundesen, Helle Wohlleben, Tine Rasmussen, Christoph Patrick Beier, Steinbjørn Hansen, Bjarne Winther Kristensen
The tyrosine kinase receptor c-Met has been suggested to be involved in crucial parts of glioma biology like tumor stemness, growth and invasion. The aim of this study was to investigate the prognostic value of c-Met in a population-based glioma patient cohort. Tissue samples from 238 patients with WHO grade I, II, III and IV tumors were analyzed using immunohistochemical staining and advanced image analysis. Strong c-Met expression was found in tumor cells, blood vessels, and peri-necrotic areas. At the subcellular level, c-Met was identified in the cytoplasm and in the cell membrane...
May 2015: Journal of Neuro-oncology
https://read.qxmd.com/read/25286040/novel-approaches-for-quantifying-protein-biomarkers-in-gliomas-benefits-and-pitfalls
#34
JOURNAL ARTICLE
Rikke H Dahlrot, Mia D Sørensen, Ann Mari Rosager, Sofie Hellwege, Julie A Bangsø, Tine Rosenberg, Stine A Petterson, Jacob Klitkou, Sigurd Fosmark, Steinbjørn Hansen, Bjarne W Kristensen
The therapeutic paradigm of gliomas is changing from a general approach towards an individualized and targeted approach. Accordingly, the search for prognostic and predictive biomarkers, as well as the demand for quantitative, feasible and robust methods for biomarker analysis increases. We find that software classifiers can identify and quantify the expression of a given biomarker within different subcellular compartments and that such classifiers can exclude frequently occurring nontumor cells, thereby avoiding potential bias...
July 2014: CNS Oncology
https://read.qxmd.com/read/25283629/the-prognostic-value-of-clinical-factors-and-cancer-stem-cell-related-markers-in-gliomas
#35
JOURNAL ARTICLE
Rikke Hedegaard Dahlrot
UNLABELLED: Gliomas are the most frequent brain tumours among adults, and it is estimated that gliomas constitute half of the about 1500 new brain tumours diagnosed in Denmark every year. Existing treatment strategies include neurosurgery, radiation, and chemotherapy. Therapy selection is based on experiences from clinical trials, with the risk that the results obtained are restricted to highly selected patients only. Moreover, these studies provided only little knowledge of the clinical behaviour of the tumours...
October 2014: Danish Medical Journal
https://read.qxmd.com/read/25120750/clinical-value-of-cd133-and-nestin-in-patients-with-glioma-a-population-based-study
#36
JOURNAL ARTICLE
Rikke H Dahlrot, Steinbjørn Hansen, Stine S Jensen, Henrik D Schrøder, Jacob Hjelmborg, Bjarne W Kristensen
Cancer stem cell-related (CSC) markers have been suggested to have promising potentials as novel types of prognostic and predictive markers in gliomas. However no single CSC-related marker is currently used in clinical decisions. The aim of this study was to investigate the prognostic value of CD133 and nestin separately and in combination using a novel quantitative approach in a well-characterized population-based cohort of glioma patients. The expression of CD133 and nestin was measured by systematic random sampling in stained paraffin sections from 239 glioma patients diagnosed between 2005 and 2009...
2014: International Journal of Clinical and Experimental Pathology
https://read.qxmd.com/read/24373972/high-throughput-flow-cytometry-screening-reveals-a-role-for-junctional-adhesion-molecule-a-as-a-cancer-stem-cell-maintenance-factor
#37
JOURNAL ARTICLE
Justin D Lathia, Meizhang Li, Maksim Sinyuk, Alvaro G Alvarado, William A Flavahan, Kevin Stoltz, Ann Mari Rosager, James Hale, Masahiro Hitomi, Joseph Gallagher, Qiulian Wu, Jody Martin, Jason G Vidal, Ichiro Nakano, Rikke H Dahlrot, Steinbjørn Hansen, Roger E McLendon, Andrew E Sloan, Shideng Bao, Anita B Hjelmeland, Christian T Carson, Ulhas P Naik, Bjarne Kristensen, Jeremy N Rich
Stem cells reside in niches that regulate the balance between self-renewal and differentiation. The identity of a stem cell is linked with the ability to interact with its niche through adhesion mechanisms. To identify targets that disrupt cancer stem cell (CSC) adhesion, we performed a flow cytometry screen on patient-derived glioblastoma (GBM) cells and identified junctional adhesion molecule A (JAM-A) as a CSC adhesion mechanism essential for self-renewal and tumor growth. JAM-A was dispensable for normal neural stem/progenitor cell (NPC) function, and JAM-A expression was reduced in normal brain versus GBM...
January 16, 2014: Cell Reports
https://read.qxmd.com/read/24057325/prognostic-value-of-musashi-1-in-gliomas
#38
JOURNAL ARTICLE
Rikke H Dahlrot, Steinbjørn Hansen, Jørn Herrstedt, Henrik D Schrøder, Jacob Hjelmborg, Bjarne W Kristensen
The aim of this study was to investigate the prognostic value of the RNA-binding protein Musashi-1 in adult patients with primary gliomas. Musashi-1 has been suggested to be a cancer stem cell-related marker in gliomas, and high levels of Musashi-1 have been associated with high tumor grades and hence poor prognosis. Samples of 241 gliomas diagnosed between 2005 and 2009 were stained with an anti-Musashi-1 antibody using a fluorescent staining protocol followed by automated image acquisition and processing...
December 2013: Journal of Neuro-oncology
https://read.qxmd.com/read/23817809/a-population-based-study-of-low-grade-gliomas-and-mutated-isocitrate-dehydrogenase-1-idh1
#39
JOURNAL ARTICLE
Rikke H Dahlrot, Bjarne W Kristensen, Jacob Hjelmborg, Jørn Herrstedt, Steinbjørn Hansen
Low-grade gliomas (LGG) have a slow growth rate, but transformations into malignant gliomas with a rapid deterioration occur in many patients. The aim of this study was to evaluate clinical prognostic factors in a population-based cohort of patients with LGG. In addition we investigated the expression and prognostic value of the isocitrate dehydrogenase 1 (IDH1) R132H mutation. Seventy-four patients diagnosed between 2005 and 2009 in the Region of Southern Denmark were identified using the Danish Cancer Register and The Danish Pathology Databank...
September 2013: Journal of Neuro-oncology
https://read.qxmd.com/read/23806221/small-cell-glioblastoma-or-small-cell-carcinoma-a-case-report-and-review-of-the-literature
#40
REVIEW
Christine Hilbrandt, Sathya Sathyadas, Rikke H Dahlrot, Bjarne W Kristensen
It is often easy to distinguish between primary brain tumors and metastases based on morphology alone. However, in some cases immunohistochemistry (IHC) is necessary to obtain a diagnosis, but, as the present case report illustrates, this is not always straightforward. A 75-year old man was admitted to the hospital with left-sided loss of motor function. A MRI revealed a 6 cm tumor in the right temporoparietal area. The histology was consistent with both glioblastoma multiforme (GBM) and small cell lung carcinoma (SCLC) but IHC was suggestive of a SCLC metastasis...
July 2013: Clinical Neuropathology
keyword
keyword
36056
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.